• Microbiotica/Genentech microbiome collaboration worth up to $534 million
• Hookipa/Gilead deal for immunotherapies against HIV and Hepatitis B potentially in excess of $400 million
• F-star Gamma could receive up to $471 million through acquisition by Denali Therapeutics to deliver biologic therapeutics across the blood-brain barrier
London, 6 June 2018 - The life sciences team at International business communications consultancy Instinstif Partners is pleased to have supported three clients that are pioneering disruptive technologies to develop tomorrow’s therapeutics in their announcements around big bio-dollar deals worth some $1.4 billion.
Three deals have been closed in the last week: on 6 June, Microbiotica announced its strategic microbiome collaboration with Genentech in a deal worth up to $534 million in upfront and milestone payments; the day before on 5 June, Hookipa announced its deal with Gilead, a collaboration and license agreement to develop immunotherapies against HIV and Hepatitis B with a potential deal value worth in excess of $400 million, including upfront and milestone payments, plus research and development funding; and last week on 31 May F-star announced the early exercise by Denali Therapeutics of its option to acquire F-star Gamma, for an upfront payment of $24 million with contingent additional milestones up to $447 million.
“All three deals announced in the last week demonstrate how the potential of cutting-edge science being pioneered in Europe with the potential to deliver new therapeutic modalities is being recognised by world-class biopharma companies” said Sue Charles Instinctif Partners’ Managing Partner and global head of Life Sciences. “It’s an honour to work with F-star, Hookipa and Microbiotica, and to support and celebrate their successes.”
About Instinctif Partners Life Sciences
Instinctif Partners is a leading international business communications consultancy and has recently been awarded International Agency of the Year at the PR Week Global Awards 2017. The firm has an exceptionally strong dedicated team focused in the Life Sciences sector. This Life Sciences practice has expertise across financial, corporate, healthcare and marketing communications, and integrates design and digital into its communications mix. Offering global outreach, its client base spans pharma, biotechnology, medical devices, diagnostics, healthcare, laboratory supply and service providers in addition to venture capitalists, recruitment companies, not-for-profit, academic organisations and science-associated bodies
Sue CharlesManaging Partner